NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery

Oncology Letters

Volumn 3, Issue 1, 2012, Pages 39-44

  Xu, Heng ^a,b   Gu, Na ^a   Liu, Zhao Bo ^a   Zheng, Min ^c   Xiong, Fang ^a   Wang, Si Ying ^b   Li, Ning ^a   Lu, Jun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c Hangzhou High Throughput Drug Screening Center   (China)

Author keywords

Early recurrence; Hepatocellular carcinoma; NY ESO 1

Indexed keywords

NY ESO 1 ANTIGEN;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER RECURRENCE; CANCER SURGERY; CANCER TISSUE; CELL CYCLE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RELAPSE;

EID: 84855212187     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.441     Document Type: Article

References (21)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Venook AP: Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 12: 1323-1334, 1994.
3. Chen YT, Scanlan MJ, Sahin U, et al: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94: 1914-1918, 1997.
4. Chen YT, Gure AO, Tsang S, et al: Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 95: 6919-6923, 1998.
5. Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ and Rosenberg SA: A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol 161: 3598-3606, 1998.
6. Perez D, Hauswirth F, Jager D, et al: Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors. Int J Cancer 128: 2947-2952, 2011.
7. Svobodova S, Browning J, Macgregor D, et al: Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. Eur J Cancer 47: 460-469, 2010.
8. Chen CH, Chen GJ, Lee HS, et al: Expressions of cancer-testis antigens in human hepatocellular carcinomas. Cancer Lett 164: 189-195, 2001.
9. Luo G, Huang S, Xie X, et al: Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun 2: 11, 2002.
10. Korangy F, Ormandy LA, Bleck JS, et al: Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10: 4332-4341, 2004.
11. Peng JR, Chen HS, Mou DC, et al: Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett 219: 223-232, 2005.
12. Zhang WM, Xiao G, Xie D, Zhang M, Guo AL and Wen JM: [Correlation of NY-ESO-1 gene and protein expression to metastasis and clinicopathologic features of hepatocellular carcinoma]. Ai Zheng 24: 622-626, 2005.
13. Zhang WM, Xiao G, Zhang M, Guo AL, Dong Y and Wen JM: [Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma]. Zhonghua Bing Li Xue Za Zhi 34: 202-205, 2005.
14. Nakamura S, Nouso K, Noguchi Y, et al: Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol 21: 1281-1285, 2006.
15. Lu Y, Wu LQ, Lu ZH, Wang XJ and Yang JY: Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma. Chin Med J (Engl) 120: 1042-1046, 2007.
16. Wang XY, Chen HS, Luo S, Zhang HH, Fei R and Cai J: Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues. Oncol Rep 21: 713-719, 2009.
17. Abassi YA, Jackson JA, Zhu J, O'Connell J, Wang X and Xu X: Label-free, real-time monitoring of IgE-mediated mast cell activation on microelectronic cell sensor arrays. J Immunol Methods 292: 195-205, 2004.
18. Perez D, Herrmann T, Jungbluth AA, et al: Cancer testis antigen expression in gastrointestinal stromal tumors: new markers for early recurrence. Int J Cancer 123: 1551-1555, 2008.
19. Konishi J, Toyooka S, Aoe M, et al: The relationship between NY-ESO-1 mRNA expression and clinicopathological features in non-small cell lung cancer. Oncol Rep 11: 1063-1067, 2004.
20. Velazquez EF, Jungbluth AA, Yancovitz M, et al: Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. Cancer Immun 7: 11, 2007.
21. Zhou JX, Li Y, Chen SX and Deng AM: Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma. J Exp Clin Cancer Res 30: 2, 2011.